Sign inJoin waitlistJoin the waitlist

HS

Howard Scher

Chief, Genitourinary Oncology Service, Department of Medicine · New York Presbyterian Hospital

Credentials: · ·

History

Genitourinary Oncology Service Division · New York Presbyterian Hospital
Present

Medical Oncology
1979–1981
Internal Medicine
1976–1979
New York University Grossman School of Medicine
1972–1976

Research

Increased survival with enzalutamide in prostate cancer after chemotherapy
New England Journal of Medicine · 2012 · First of 21 authors · Corresponding · 3,725 citations
Abiraterone and increased survival in metastatic prostate cancer
New England Journal of Medicine · 2011 · 3,621 citations
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Nature Genetics · 2019 · 3,156 citations

MM
Michael Morris
127 papers · 2 as a fellow
SS
Susan Slovin
75 papers · 11 as a fellow
SL
Steven Larson
66 papers
DR
Dana Rathkopf
64 papers
WK
Wm Kelly
61 papers · 22 as a fellow
Cora Sternberg
58 papers
VR
Victor Reuter
52 papers
DD
Daniel Danila
49 papers
CR
Charles Ryan
38 papers
David Solit
37 papers · 6 as a fellow
HH
Harry Herr
36 papers · 2 as a fellow
Wassim Abida
35 papers · 2 as a fellow

Grants

SPORE in Prostate Cancer
National Cancer Institute · P50
Contact PI · $32.8M · Sloan-Kettering Inst Can Research
2001–2027
The Impact of DNA Damage Repair Abnormalities in Prostate Cancer
National Cancer Institute · P01
Project lead · $1.7M · Sloan-Kettering Inst Can Research
2019–2026
Evaluation of the Effect of Patient-Context Factors and Sample Acquisition on the Quality and Analytical Performance of Cell-Free DNA and Circulating Tumor Cells Profiling Assays in Prostate Cancer Pa
National Cancer Institute · U01
PI · $1.8M · Sloan-Kettering Inst Can Research
2020–2025
Biologic Effects of 17aa Geldanamycin
National Cancer Institute · R21
Contact PI · $599.4K · Sloan-Kettering Inst Can Research
1999–2002

Clinical trials

3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy
Principal investigator · Completed · Phase 2
Memorial Sloan Kettering Cancer Center
2012–2020
Identification of Predictive Factors for Survival of Patients With Recurrent Prostate Cancer From Clinical Features, Tissue Image Features and Molecular Biomarker Data
Principal investigator · Completed
Memorial Sloan Kettering Cancer Center
2004–2010
Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer
Principal investigator · Completed · Phase 1, Phase 2
Memorial Sloan Kettering Cancer Center
2004–2008
Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle
Principal investigator · Completed · Phase 2
Memorial Sloan Kettering Cancer Center
2001–2009